CCI
ACHN

Columbus Circle Investors’s Achillion Pharmaceuticals ACHN Stock Holding History

Columbus Circle Investors’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-134,388
Closed -$1.09M – 323
2016
Q3 		$1.09M Buy
134,388
+24,214
+22% +$206K 0.01% 250
2016
Q2 		$859K Buy
110,174
+34,720
+46% +$298K 0.01% 234
2016
Q1 		$583K Sell
75,454
-170,680
-69% -$1.25M 0.01% 250
2015
Q4 		$2.66M Sell
246,134
-181,655
-42% -$1.65M 0.02% 237
2015
Q3 		$2.96M Buy
427,789
+110,054
+35% +$897K 0.02% 231
2015
Q2 		$2.81M Buy
317,735
+131,409
+71% +$1.24M 0.02% 237
2015
Q1 		$1.84M Sell
186,326
-131,440
-41% -$1.64M 0.01% 251
2014
Q4 		$3.89M Buy
317,766
+158,181
+99% +$1.93M 0.03% 235
2014
Q3 		$1.59M Sell
159,585
-160,574
-50% -$1.49M 0.01% 226
2014
Q2 		$2.42M Buy
+320,159
New +$1.28M 0.02% 246
2013
Q3 		– Sell
-174,081
Closed -$1.42M – 349
2013
Q2 		$1.42M Buy
+174,081
New +$1.33M 0.01% 257

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Columbus Circle Investors's ACHN Position: Q4 2016 in Review

Columbus Circle Investors sold out of Achillion Pharmaceuticals (ACHN) in Q4 2016, closing a stake of 134,388 shares — an estimated $1.09M sold.

Columbus Circle Investors first reported a position in ACHN in Q2 2013 and held it in 11 quarters. The position peaked at $3.89M in Q4 2014. 140 funds tracked by Wall St. Rank hold ACHN as of Q4 2016.

  • Columbus Circle Investors reported no remaining Achillion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Columbus Circle Investors sold 134,388 Achillion Pharmaceuticals shares in Q4 2016, an estimated $1.09M.
  • Columbus Circle Investors first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 11 quarters.
  • Columbus Circle Investors's Achillion Pharmaceuticals position peaked at $3.89M in Q4 2014.
  • 140 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2016.

Based on Columbus Circle Investors's 13F filing for Q4 2016, filed 2 Feb 2017.